Abstract:OBJECTIVE:To investigate the predictive value of prostate-specific antigen (PSA) and Gleason sum for results of radionuclide bone scintigraphy in prostate cancer patients, in order to determine when to perform a radionuclide bone scintigraphy in Chinese patients with newly diagnosed prostate cancer. METHODS:We retrospectively reviewed the charts of 624 consecutive patients with a pathology diagnosis of prostate cancer hospitalized in Department of Urology, Peking University First Hospital between Jan. 1994 and Dec. 2005, and evaluated the relationships between results of bone scintigraphy and serum tPSA, and between bone scintigraphy and Gleason sum. The receiver operating characteristics (ROC) curves were analyzed to determine the cut-off values of tPSA and Gleason sum for predicting positive results of bone scintigraphy. RESULTS:In the study, 443 patients underwent both a radionuclide bone scan and a serum PSA test prior to treatment, of whom, 216 (48.8%) got positive results, and 338 also possessed the Gleason sum for pathological evaluation. The serum tPSA levels were significantly higher in patients with positive results of the bone scan ( median: 71.00 μg/L; range: 1.30-2 400.00 μg/L) than those with negative results ( median: 60.00 μg/L; range: 0.60-201.00 μg/L; rank P<0.001), and the Gleason sums were also significantly higher in positive-bone-scan patients than in negative-bone-scan patients (7.7±1.5 vs. 6.7±1.8, P<0.001). Linear regression analysis suggested significant positive correlation between the results of the bone scan and the two afore-mentioned parameters, respectively (lg[PSA]: r=0.933, B=0.352, P=0.001; Gleason sum: r=0.971, B=0.096, P<0.001). The incidence of a positive bone scan result was 9.0% in patients with tPSA<10 μg/L and 3.8% in patients with Gleason sum<5. When the indication for bone scan was established as tPSA>15 μg/L or Gleason sum≥7,its sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy for positive results were 97.5%, 24.7%, 54.4%, 91.5% and 60.0%, respectively. CONCLUSION:In patients with prostate cancer, their positive results of the bone scan are significantly positively correlated to their higher PSA levels and higher Gleason sums, respectively. Our analyses suggest that a patient with newly diagnosed prostate cancer would not need to undergo radionuclide bone scintigraphy when the PSA level is lower than 10 μg/L and Gleason sum is less than 5, and that a prostate cancer patient with tPSA>15 μ g/L or Gleason sum≥7 should take a bone scintigraphy.

Clinical Significance of PSA and ECT in Diagnosis of Prostate Cancer with Bone Metastasis

The Application of Radionuclide Bone Scintigraphy,Serum PSA and ALP Measurement in Diagnosis of Bone Metastasis in Prostate Cancer Patients

Association between 99mTc-PSMA SPECT/CT imaging and prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels post-endocrine therapy in patients with prostate cancer and bone metastases

Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction

Technetium-99m-methylene diphosphonate single photon emission computed tomography/computed tomography combined with prostate-specific antigen/free prostate-specific antigen ratio for bone metastasis of prostate cancer

Clinical Diagnosis of Bone Metastasis from Prostate Cancer:Comparison of MRI and Bone Scintigraphy

Clinical Analysis of Prostate Cancer with Bone Metastasis: A Report of 63 Cases

Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial

Can bone scan be spared in asymptomatic prostate cancer patients at the initial stage of diagnosis?

Clinical analysis of prostate cancer with bone pain as the first clinical manifestation:report of 51 cases

When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study

Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases

Predictive Value of Prostate-Specific Antigen and Gleason Sum for Results of Radionuclide Bone Scintigraphy in Patients with Prostate Cancer

Prostate-specific membrane antigen PET versus [99mTc]Tc-MDP bone scan for diagnosing bone metastasis in prostate cancer: a head-to-head comparative meta-analysis

The diagnostic significance of tiyeⅠcollagen-cross-linked N telopeptide in bone metastasis of prostate cancer

Value of PSMA-SPECT/CT in the precise treatment of metastatic lesions in patients with prostate cancer

Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis

Prognosis of Prostate Cancer and Bone Metastasis Pattern of Patients: a SEER-based Study and a Local Hospital Based Study from China

Clinical significance of TrACP in diagnosis and prediction of bone metastasis in prostate cancer

Clinical value of 99mTc-PSMA SPECT/CT in detection of prostate cancer

Should Bone Scan Be Performed in Chinese Prostate Cancer Patients at the Time of Diagnosis?